Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine

血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗

• 批准号: 8054408
• 负责人: Susan Dana Jones
• 金额: $ 23.75万
• 依托单位: IMMURX LLC
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2011-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8054408
• 关键词: Adjuvant; Agonist; Angiogenesis Inhibitors; Angiogenic Factor; Angiogenic Switch; Ascaridil; Autologous; B-Cell Lymphomas; Cancer Etiology; Cancer Vaccines; Cells; Cellular Immunity; Chemosensitization; Clinic; Clinical; Combined Modality Therapy; Combined Vaccines; Cyclophosphamide; Data; Development; Effector Cell; Ensure; Fibroblast Growth Factor; Goals; Growth; Health; Immune; Immune response; Immune system; Immunity; Immunologics; Infiltration; Leukocytes; Mast Cell Neoplasm; Melanoma Vaccine; Methods; Modality; Modeling; Mus; Myelogenous; Neoplasm Metastasis; Ovarian Carcinoma; Play; Process; Production; Protocols documentation; Publishing; Regimen; Regulatory T-Lymphocyte; Relative (related person); Research Personnel; Site; Study models; Suppressor-Effector T-Lymphocytes; TNFRSF5 gene; Technology; Testing; Therapeutic; Time; Treatment Protocols; Tumor Angiogenesis; Tumor Antigens; Tumor Burden; Tumor Immunity; Vaccination; Vaccine Adjuvant; Vaccine Antigen; Vaccine Design; Vaccine Therapy; Vaccines; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; Wound Healing; acquired immunity; angiogenesis; antiangiogenesis therapy; base; bladder Carcinoma; chemotherapeutic agent; chemotherapy; clinically relevant; experience; immunogenic; improved; mast cell; melanoma; neoplastic cell; neovascularization; programs; receptor; response; tumor; tumor growth; tumorigenesis; vaccine-induced immunity

DESCRIPTION (provided by applicant): The early infiltration by leukocytes into the tumor microenvironment leads to neovascularization, enhanced tumor growth, metastasis and lethality of the host. Notably, leukocytes enable tumor establishment, as suggested early on by Virchow in 1826 and proven more recently by others (e.g. Manning et al, 2007 Clin Ca Res 13:3951; review Wasiuk/Noelle et al. 2009 Clin Exp Immunol 155:140). Our own preliminary data (Noelle et al.) show that if one interferes with the early infiltration of inhibitory leukocytes, one can greatly enhance the development of protective tumor immunity and survival of the host. Further, eradicating mast cells increases survival from 5% to over 80% of mice to immunogenic tumors. In lieu of eradicating mast cells, our studies have evaluated if anti-tumor immunity can be enhanced by blocking angiogenesis. The preliminary data show that the use of anti-VEGFR2 Ab, which is functionally equivalent to the eradication of mast cells, can similarly increase survival of the host to immunogenic tumors. The premise of this proposal is that tumor vaccines that induce immunity to a non-immunogenic tumor like B16 melanoma, require an anti-angiogenic/mast cell approach to ensure that tumor site inhibitory leukocytes do not inhibit otherwise highly effective tumor-specific cell mediated immunity (CMI), as well as a cytoreduction/chemotherapeutic agent to provide immunologic space for effective CMI to develop. While most anti-angiogenesis studies focus directly on tumor site vasculature, investigators have begun to evaluate the impact of blocking angiogenesis on host responses to tumors. Based on our studies and those published, we hypothesize that anti-angiogenic factors will greatly enhance the efficacy of our tumor vaccine to elicit superior protective, acquired, tumor-specific cell-mediated immunity. In Aim 1 we propose to use our experience in developing melanoma vaccines to provide proof-of-concept for a combination vaccine that 1) uses our proprietary CD40/TLR agonist adjuvant vaccine to induce superior CMI against tumors relative to vaccine technologies currently used by others, and 2) broadly abrogates angiogenesis/mast cell-induced inhibition of CMI across several additional tumor models. Furthermore, in Aim 2, cytoreductive/chemotherapy methods, shown to be somewhat effective in the clinic, will be overlaid on this approach to test for additional efficacy. PUBLIC HEALTH RELEVANCE: The premise of this proposal is that tumor vaccines that induce immunity to poorly or non-immunogenic tumors like B16 melanoma, require an anti-angiogenic/mast cell approach plus cytoreductive chemotherapy to ensure that the tumor site does not inhibit otherwise highly effective anti-tumor leukocytes. The approach here, based on our preliminary results, is to develop a combination therapy using our proprietary anti-CD40/TLR adjuvant vaccine combined with blocking Ab to the angiogenesis factor VEGFR2 as well as the cytoreductive chemotherapeutic Cytoxan. We predict that we can improve anti-tumor immunity against a range of otherwise hard-to-treat tumor states.

描述(申请人提供)：白细胞早期渗入肿瘤微环境，导致新生血管，促进肿瘤生长，转移和宿主的致命性。值得注意的是，正如1826年Virchow早期提出的并被其他人证实的那样，白细胞促进了肿瘤的形成(例如，Manning等人，2007年Clin Ca Res 13：3951；回顾Wasiuk/Noelle等人)。2009年临床经验免疫155：140)。我们自己的初步数据(Noelle等人)表明如果干预早期抑制性白细胞的渗透，可以极大地提高肿瘤保护性免疫的发展和宿主的生存。此外，根除肥大细胞可将小鼠对免疫原性肿瘤的存活率从5%提高到80%以上。代替根除肥大细胞，我们的研究评估了是否可以通过阻断血管生成来增强抗肿瘤免疫。初步数据显示，使用功能相当于根除肥大细胞的抗VEGFR2抗体，可以类似地提高免疫原性肿瘤宿主的存活率。这项建议的前提是，诱导对非免疫原性肿瘤(如B16黑色素瘤)免疫的肿瘤疫苗需要抗血管生成/肥大细胞方法，以确保肿瘤部位抑制白细胞不会抑制其他高效的肿瘤特异性细胞介导免疫(CMI)，以及细胞减少/化疗药物，以提供有效CMI发展的免疫学空间。 虽然大多数抗血管生成研究直接集中在肿瘤部位的血管生成上，但研究人员已经开始评估阻断血管生成对宿主对肿瘤反应的影响。基于我们的研究和已发表的研究，我们假设抗血管生成因子将极大地增强我们的肿瘤疫苗的效力，以诱导更好的保护性、获得性、肿瘤特异性细胞介导免疫。在目标1中，我们建议利用我们在开发黑色素瘤疫苗方面的经验为组合疫苗提供概念验证，该联合疫苗1)使用我们专有的CD40/TLR激动剂佐剂疫苗来诱导相对于其他公司目前使用的疫苗技术更好的针对肿瘤的CMI，以及2)在其他几种肿瘤模型中广泛地消除血管生成/肥大细胞诱导的CMI抑制。此外，在目标2中，在临床上被证明有一定效果的细胞减少/化疗方法将覆盖在这种方法上，以测试额外的疗效。 公共卫生相关性：这项建议的前提是，诱导对低免疫原性或非免疫原性肿瘤(如B16黑色素瘤)免疫的肿瘤疫苗需要抗血管生成/肥大细胞方法加上细胞减少化疗，以确保肿瘤部位不会抑制其他高效的抗肿瘤白细胞。基于我们的初步结果，我们的方法是开发一种联合疗法，使用我们专有的抗CD40/TLR佐剂疫苗，结合血管生成因子VEGFR2的阻断抗体以及细胞减少化疗药物环磷酰胺。我们预测，我们可以提高对一系列难以治疗的肿瘤状态的抗肿瘤免疫力。